Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Smac mimetic compounds (SMCs) sensitize cancer cells to apoptosis by antagonizing Inhibitor of Apoptosis proteins.
• SMCs synergize with oncolytic viruses like VSVΔ51, dependent on TNF-α and type I interferon.
• Existing therapies require higher viral doses and struggle with efficacy.

Purpose of the Study:

• To engineer an oncolytic virus to enhance SMC-mediated anti-cancer synergy.
• To investigate the efficacy of a TNF-α-armed VSVΔ51 combined with an SMC (LCL161).
• To elucidate the mechanisms of action for this novel combination therapy.

Main Methods:

• Generation of TNF-α-armed VSVΔ51.
• Co-administration of TNF-α-armed VSVΔ51 with LCL161 in preclinical cancer models.
• Assessment of survival rates, tumor cell death, and tumor vascularization.

Main Results:

• A lower viral dose of TNF-α-armed VSVΔ51 with LCL161 significantly improved survival rates compared to unarmed VSVΔ51 and LCL161.
• Observed bystander effect: TNF-α spread from infected cells induced death in uninfected cells.
• Induced vascular collapse in solid tumors, leading to increased tumor cell death.

Conclusions:

• Cytokine-engineered oncolytic viruses offer enhanced therapeutic potential.
• Combination of TNF-α-armed VSVΔ51 and LCL161 represents a promising new cancer immunotherapy strategy.
• This approach demonstrates potent anti-tumor activity through multiple mechanisms.